Skip to main content

ELB011 (anti-CD160 ophtalmology)

Mon, 07/02/2018 - 15:00 - Fri, 07/02/2021 - 15:30
  • Efficacy and safety are consistently demonstrated in several in vivo preclinical models
  • Anti-CD160 is a potent inhibitor of ocular v
Thu, 02/22/2018 - 17:00
  • ELB011, a first-in-class antibody program, demonstrates an anti-angiogenic effect on the formation of new blood vessels which cause cert

Tue, 02/16/2016 - 17:00
  • Having acquired in June 2015 the assets of CD160 in the field of ophthalmology, ElsaLys Biotech strengthens its intellectual property an

Thu, 07/02/2015 - 17:00
  • Developed so far by MABLIFE in ophthalmology, the anti-CD160 antibody has also a significant therapeutic potential in oncology.

STAY IN TOUCH WITH OUR LATEST NEWS

Subcribe to our newsletter